Journal: BMC Oral Health
Article Title: Assessment and comparative study of diosgenin doses in alleviating experimental periodontitis
doi: 10.1186/s12903-024-04646-3
Figure Lengend Snippet: Immunohistochemical expression results for all groups according to the streptavidin–biotin method. Negative-to-slight expression in the control group; marked decreases in alkaline phosphatase (ALP), Bcell lymphoma 2 (Bcl-2), bone morphogenetic protein 2 (BMP-2), Col-1, and osteocalcin (OCN) but increases in Bcl-2-associated X protein (BAX) and receptor activator of NF-κB ligand (RANKL) in the periodontitis (P) group; and amelioration by diosgenin 48 mg/kg/day (DG-48) and diosgenin 96 mg/kg/day (DG-96) in those groups. The arrows indicate cells expressing markers; the bars represent 50 μm
Article Snippet: Sections were immunohistochemically stained at 1/100 dilution for all primary antibodies using anti-BMP 2 (ab59348; all from Abcam plc, Cambridge, UK), anti-RANKL (ab216484), anti-ALP (ab224335), Bax (ab53154), anti-Bcl-2 (ab59348), anti-Col-1 (ab34710) and anti-OCN (ab93876) antibody kits according to the manufacturer’s recommendations.
Techniques: Immunohistochemical staining, Expressing, Control